Conba has released its 2026 interim report. Total operating revenue was 3.701 billion yuan, up 10.21% year on year, and net profit attributable to the parent company was 378 million yuan, up 6.83% year on year. Net cash inflow from operating activities was 541 million yuan, up 35.10% year on year, marking a second consecutive year of growth. The company's debt-to-asset ratio was 29.37%, gross margin was 56.80%, return on equity was 5.35%, and diluted earnings per share was 0.15 yuan. The number of shareholders was 90,800, and the top ten shareholders held 38.72% of total share capital.
Zhejiang CONBA Pharmaceutical Co LtdNet profit up 6.83% and revenue up 10.21% in interim report.
